GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neurizon Therapeutics NUZ.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.06

-6.25%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2024

Revenue

A$866,200

FY2015FY2024

Net income

−A$7.7m

FY2015FY2024

Free cash flow

−A$5.2m

FY2015FY2024

Shareholders' equity

A$10.2m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
RevenueA$866,200A$949,600A$4.5mA$3.7mA$4.1mA$4.4mA$3.3mA$3.3mA$2.8mA$2.4m
Research and developmentA$3.8mA$1.0mA$758,700A$554,100A$605,400A$1.0mA$463,900A$329,300A$702,000A$629,200
Operating income−A$5.8m−A$1.6m−A$1.6m−A$1.3m−A$1.2m−A$1.5m−A$2.5m−A$1.3m−A$1.8m−A$1.9m
Net income−A$7.7m−A$6.2m−A$1.7m−A$1.3m−A$1.4m−A$1.6m−A$2.5m−A$1.3m−A$3.9m−A$1.9m
Diluted earnings per share-0.02-0.00-0.01-0.00-0.00-0.01-0.02-0.01-0.04-0.02

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assetsA$11.1mA$6.1mA$10.1mA$11.0mA$10.7mA$8.6mA$8.4mA$8.2mA$6.3mA$9.5m
Cash and short-term investmentsA$9.7mA$2.7mA$2.4mA$3.0mA$2.9mA$2.1mA$1.9mA$2.6mA$886,100A$3.4m
Total liabilitiesA$896,600A$2.2mA$2.2mA$2.1mA$2.2mA$1.1mA$1.2mA$1.3mA$1.2mA$683,200
Debt—A$1.0mA$1.4mA$1.3mA$1.5mA$324,600A$425,600A$487,500A$607,900A$39,500
Shareholders' equityA$10.2mA$3.9mA$7.8mA$8.9mA$8.5mA$7.5mA$7.1mA$6.9mA$5.0mA$8.8m
Shares outstanding371m321m322m321m301m219m162m137m106m87m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−A$5.2m−A$1.6m−A$1.3m−A$938,000−A$1.3m−A$1.6m−A$1.6m−A$1.3m−A$1.6m−A$1.8m
Capital spending—−A$34,800−A$43,400−A$101,700−A$30,200−A$146,700−A$868,900−A$57,000−A$1.5m−A$109,700
Free cash flow−A$5.2m−A$1.6m−A$1.4m−A$1.0m−A$1.3m−A$1.7m−A$2.4m−A$1.3m−A$3.1m−A$1.9m

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022Dec 2021
RevenueA$126,000A$1.8mA$4,900A$861,300A$949,600A$967,200A$2.8mA$1.7m
Operating income−A$9.3m−A$7.3m−A$4.2m−A$1.6mA$2.0m−A$67,900−A$437,800−A$1.2m
Net income−A$9.3m−A$7.3m−A$7.3m−A$389,200−A$6.2m−A$21,200−A$480,700−A$1.2m
Diluted earnings per share-0.02-0.01-0.02-0.00-0.00-0.00-0.00-0.00
Cash from operations—−A$5.0m−A$5.0m—−A$1.0m———
Total assetsA$4.4mA$15.5mA$11.1m——A$10.0mA$10.1mA$10.7m
Cash and short-term investmentsA$4.2mA$10.1mA$9.7m——A$2.1mA$2.4mA$2.6m
Debt—————A$965,400A$1.0mA$1.1m
Shareholders' equityA$2.8mA$11.9mA$10.2m——A$7.7mA$7.8mA$8.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-38.2%-27.6%-8.1%
Operating income66.4%31.0%15.9%
Net income79.0%37.7%19.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-405.6%-102.4%-70.3%-67.6%
Net margin-764.7%-169.3%-107.3%-95.6%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings-8.2-5.9-12.1-24.0-23.2-15.2-2.3-5.6-1.4-3.4
Price to sales72.838.94.68.87.75.41.82.22.02.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 30 Oct 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.